Literature DB >> 24899571

Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis.

Maria B Nishishinya1, Claudia A Pereda, Santiago Muñoz-Fernández, José M Pego-Reigosa, Iñigo Rúa-Figueroa, José-Luis Andreu, Mónica Fernández-Castro, José Rosas, Estibaliz Loza Santamaría.   

Abstract

To identify risk and predictors of lymphoma or lymphoproliferative disease in patients with primary Sjögren syndrome. Articles were identified through a comprehensive search strategy in Medline, Embase and Cochrane CENTRAL. Studies had to investigate primary Sjögren syndrome patients, 18 years of age or older, with the goal of examining potential clinical, immunological and hematological risk factors for lymphoma or lymphoproliferative disease. The quality of the studies was graded using the Oxford Levels of Evidence Scale. Whenever possible, the authors created evidence tables and performed meta-analysis. Of 900 studies identified, 18 were selected for inclusion. These studies provided data from over 15,000 patients (90 % female) for analysis. Lymphadenopathy, parotid enlargement, palpable purpura, low C4 serum levels and cryoglobulins were the most consistent non-Hodgkin´s lymphoma/lymphoproliferative disease predictors. Additionally, some of the studies identified splenomegaly, low C3 serum levels, lymphopenia and neutropenia as significant prognostic factors. The detection of germinal center-like lesions in primary Sjögren Syndrome diagnostic salivary biopsies was also proposed as highly predictive of non-Hodgkin´s lymphoma. In contrast, anemia, anti-Ro, anti-La, antinuclear antibodies, rheumatoid factor, male gender and hypergammaglobulinemia were not associated with lymphoma or lymphoproliferative disease. Patients with primary Sjögren syndrome have an increased risk of lymphoma or lymphoproliferative disease compared to the general population. Ascertaining relevant and reliable predictors in this patient population would greatly facilitate the identification of patients at elevated risk for closer monitoring in the context of limited resources.

Entities:  

Mesh:

Year:  2014        PMID: 24899571     DOI: 10.1007/s00296-014-3051-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  45 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 2.  Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics.

Authors:  Karin Ekström Smedby; Eva Baecklund; Johan Askling
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

3.  Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; G Balestrieri; W Bencivelli; R M Bernstein; K B Bjerrum; S Braga; J Coll; S de Vita
Journal:  Arthritis Rheum       Date:  1993-03

4.  Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjögren's syndrome.

Authors:  G Valesini; R Priori; D Bavoillot; J Osborn; M G Danieli; N Del Papa; R Gerli; M Pietrogrande; M G Sabbadini; F Silvestris; L Valsecchi
Journal:  J Rheumatol       Date:  1997-12       Impact factor: 4.666

5.  Primary Sjögren's syndrome in the North East of England: a long-term follow-up study.

Authors:  B K Davidson; C A Kelly; I D Griffiths
Journal:  Rheumatology (Oxford)       Date:  1999-03       Impact factor: 7.580

Review 6.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 7.  Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis.

Authors:  Yan Liang; Zaixing Yang; Baodong Qin; Renqian Zhong
Journal:  Ann Rheum Dis       Date:  2013-05-17       Impact factor: 19.103

8.  Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects.

Authors:  Evangelia Baimpa; Issa J Dahabreh; Michael Voulgarelis; Haralampos M Moutsopoulos
Journal:  Medicine (Baltimore)       Date:  2009-09       Impact factor: 1.889

9.  B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome.

Authors:  Adrianos Nezos; Aristea Papageorgiou; George Fragoulis; Dimitrios Ioakeimidis; Michael Koutsilieris; Athanasios G Tzioufas; Haralampos M Moutsopoulos; Michael Voulgarelis; Clio P Mavragani
Journal:  J Autoimmun       Date:  2013-07-09       Impact factor: 7.094

10.  Possible Mechanisms of Lymphoma Development in Sjögren's Syndrome.

Authors:  Lingli Dong; Yu Chen; Yasufumi Masaki; Toshiro Okazaki; Hisanori Umehara
Journal:  Curr Immunol Rev       Date:  2013-02
View more
  17 in total

Review 1.  Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies.

Authors:  Abha G Singh; Siddharth Singh; Eric L Matteson
Journal:  Rheumatology (Oxford)       Date:  2015-09-27       Impact factor: 7.580

Review 2.  The Diagnosis and Treatment of Sjögren's Syndrome.

Authors:  Ana-Luisa Stefanski; Christian Tomiak; Uwe Pleyer; Thomas Dietrich; Gerd Rüdiger Burmester; Thomas Dörner
Journal:  Dtsch Arztebl Int       Date:  2017-05-26       Impact factor: 5.594

3.  Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma.

Authors:  Gaetane Nocturne; Elena Pontarini; Michele Bombardieri; Xavier Mariette
Journal:  Rheumatology (Oxford)       Date:  2019-03-05       Impact factor: 7.580

4.  Breast MALT lymphoma and AL amyloidosis complicating Sjögren's syndrome.

Authors:  Nabil Belfeki; Salima Bellefquih; Anne Bourgarit
Journal:  BMJ Case Rep       Date:  2019-04-11

Review 5.  The relationships between cancer and autoimmune rheumatic diseases.

Authors:  Laura C Cappelli; Ami A Shah
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-02-03       Impact factor: 4.098

Review 6.  Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers.

Authors:  Andreas V Goules; Athanasios G Tzioufas
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

7.  Long-term follow-up in primary Sjögren's syndrome reveals differences in clinical presentation between female and male patients.

Authors:  Jorge I Ramírez Sepúlveda; Marika Kvarnström; Per Eriksson; Thomas Mandl; Katrine Brække Norheim; Svein Joar Johnsen; Daniel Hammenfors; Malin V Jonsson; Kathrine Skarstein; Johan G Brun; Lars Rönnblom; Helena Forsblad-d'Elia; Sara Magnusson Bucher; Eva Baecklund; Elke Theander; Roald Omdal; Roland Jonsson; Gunnel Nordmark; Marie Wahren-Herlenius
Journal:  Biol Sex Differ       Date:  2017-08-08       Impact factor: 5.027

8.  Cigarette smoking and the risk of primary Sjögren's syndrome: a nested case control study.

Authors:  Peter Olsson; Carl Turesson; Thomas Mandl; Lennart Jacobsson; Elke Theander
Journal:  Arthritis Res Ther       Date:  2017-03-07       Impact factor: 5.156

Review 9.  Microbial Agents as Putative Inducers of B Cell Lymphoma in Sjögren's Syndrome through an Impaired Epigenetic Control: The State-of-The-Art.

Authors:  Rossella Talotta; Piercarlo Sarzi-Puttini; Fabiola Atzeni
Journal:  J Immunol Res       Date:  2019-01-06       Impact factor: 4.818

10.  Sjögren Syndrome Complicated by Mucosa-Associated Lymphoid Tissue Lymphoma and Lymphocytic Interstitial Pneumonia.

Authors:  Fatma Ahmed; Osama Raslan; Razi Muzaffar; Nadeem Parkar; Nitin Marwaha; Medhat M Osman
Journal:  Front Oncol       Date:  2015-08-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.